A detailed history of Pacer Advisors, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Pacer Advisors, Inc. holds 67,740 shares of EXEL stock, worth $1.76 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
67,740
Previous 64,927 4.33%
Holding current value
$1.76 Million
Previous $1.54 Million 1.17%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$20.34 - $23.73 $57,216 - $66,752
2,813 Added 4.33%
67,740 $1.52 Million
Q1 2024

May 10, 2024

BUY
$20.17 - $23.93 $59,582 - $70,689
2,954 Added 4.77%
64,927 $1.54 Million
Q4 2023

Jan 16, 2024

BUY
$19.25 - $24.13 $450,796 - $565,076
23,418 Added 60.74%
61,973 $1.49 Million
Q3 2023

Nov 13, 2023

SELL
$19.04 - $22.74 $353,096 - $421,713
-18,545 Reduced 32.48%
38,555 $842,000
Q2 2023

Jul 12, 2023

SELL
$18.17 - $20.48 $22.1 Million - $24.9 Million
-1,213,672 Reduced 95.51%
57,100 $1.09 Million
Q1 2023

May 02, 2023

BUY
$16.3 - $19.41 $4.07 Million - $4.84 Million
249,524 Added 24.43%
1,270,772 $24.7 Million
Q4 2022

Feb 06, 2023

BUY
$14.96 - $17.39 $15.3 Million - $17.8 Million
1,021,248 New
1,021,248 $16.4 Million
Q2 2022

Aug 12, 2022

BUY
$17.44 - $23.16 $14.2 Million - $18.9 Million
816,449 Added 8517.99%
826,034 $17.2 Million
Q1 2022

Apr 05, 2022

SELL
$17.03 - $22.67 $2.26 Million - $3.01 Million
-132,990 Reduced 93.28%
9,585 $217,000
Q4 2021

Feb 03, 2022

BUY
$15.84 - $21.88 $1.71 Million - $2.36 Million
107,706 Added 308.89%
142,575 $2.61 Million
Q3 2021

Oct 15, 2021

BUY
$16.3 - $21.14 $32,583 - $42,258
1,999 Added 6.08%
34,869 $737,000
Q2 2021

Jul 21, 2021

SELL
$17.95 - $25.56 $67,204 - $95,696
-3,744 Reduced 10.23%
32,870 $599,000
Q1 2021

Apr 05, 2021

SELL
$20.53 - $25.22 $123,672 - $151,925
-6,024 Reduced 14.13%
36,614 $827,000
Q4 2020

Jan 20, 2021

SELL
$18.39 - $24.8 $682,636 - $920,576
-37,120 Reduced 46.54%
42,638 $856,000
Q3 2020

Oct 19, 2020

BUY
$20.67 - $26.94 $944,288 - $1.23 Million
45,684 Added 134.07%
79,758 $1.95 Million
Q2 2020

Jul 29, 2020

SELL
$16.46 - $27.42 $268,429 - $447,165
-16,308 Reduced 32.37%
34,074 $809,000
Q1 2020

Apr 23, 2020

SELL
$14.46 - $21.8 $759,236 - $1.14 Million
-52,506 Reduced 51.03%
50,382 $979,000
Q4 2019

Feb 10, 2020

SELL
$15.15 - $18.89 $955,404 - $1.19 Million
-63,063 Reduced 38.0%
102,888 $1.81 Million
Q3 2019

Oct 10, 2019

BUY
$17.68 - $22.65 $33,397 - $42,785
1,889 Added 1.15%
165,951 $2.94 Million
Q2 2019

Aug 12, 2019

BUY
$18.93 - $24.75 $3.11 Million - $4.06 Million
164,062 New
164,062 $3.51 Million
Q4 2018

Feb 13, 2019

SELL
$13.65 - $21.8 $1.67 Million - $2.67 Million
-122,273 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$15.87 - $22.4 $1.94 Million - $2.74 Million
122,273 New
122,273 $2.17 Million
Q1 2018

May 14, 2018

SELL
$22.15 - $31.89 $95,245 - $137,127
-4,300 Closed
0 $0
Q4 2017

Feb 14, 2018

SELL
$24.23 - $30.93 $1.06 Million - $1.35 Million
-43,808 Reduced 91.06%
4,300 $131,000
Q3 2017

Nov 08, 2017

BUY
$23.35 - $29.24 $1.12 Million - $1.41 Million
48,108
48,108 $1.17 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.35B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Pacer Advisors, Inc. Portfolio

Follow Pacer Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.